WO2009124266A3 - Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof - Google Patents

Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof Download PDF

Info

Publication number
WO2009124266A3
WO2009124266A3 PCT/US2009/039498 US2009039498W WO2009124266A3 WO 2009124266 A3 WO2009124266 A3 WO 2009124266A3 US 2009039498 W US2009039498 W US 2009039498W WO 2009124266 A3 WO2009124266 A3 WO 2009124266A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkylated
semi
making
methods
ethers
Prior art date
Application number
PCT/US2009/039498
Other languages
French (fr)
Other versions
WO2009124266A2 (en
Inventor
Glenn Prestwich
Jianxing Zhang
Thomas P. Kennedy
Narayanam Rao
Xiayou Xu
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2009231634A priority Critical patent/AU2009231634B2/en
Priority to BRPI0909849A priority patent/BRPI0909849A2/en
Priority to JP2011503216A priority patent/JP5758797B2/en
Priority to CA2719666A priority patent/CA2719666C/en
Priority to EP09727633.1A priority patent/EP2281008B1/en
Priority to CN2009801208979A priority patent/CN102177180A/en
Priority to MX2010010904A priority patent/MX2010010904A/en
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Publication of WO2009124266A2 publication Critical patent/WO2009124266A2/en
Publication of WO2009124266A3 publication Critical patent/WO2009124266A3/en
Priority to US12/870,774 priority patent/US8399430B2/en
Priority to US12/870,763 priority patent/US7855187B1/en
Priority to US13/069,860 priority patent/US8343942B2/en
Priority to US13/304,292 priority patent/US8329673B2/en
Priority to US13/735,124 priority patent/US8951990B2/en
Priority to US14/613,523 priority patent/US9549945B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Described herein is the synthesis of alkylated and fluoroalkylated semi-synthetic glycosaminoglycosan ethers, referred to herein as "SAGEs." The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases and skin disorders.
PCT/US2009/039498 2008-04-04 2009-04-03 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof WO2009124266A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AU2009231634A AU2009231634B2 (en) 2008-04-04 2009-04-03 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
BRPI0909849A BRPI0909849A2 (en) 2008-04-04 2009-04-03 semi-synthetic glycosaminoglycosane ethers and methods for making and using them
JP2011503216A JP5758797B2 (en) 2008-04-04 2009-04-03 Alkylated semi-synthetic glycosaminoglycan ethers and methods for their production and use
CA2719666A CA2719666C (en) 2008-04-04 2009-04-03 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
EP09727633.1A EP2281008B1 (en) 2008-04-04 2009-04-03 Alkylated and sulfated hyaluronan compounds, methods for their preparation and use thereof
CN2009801208979A CN102177180A (en) 2008-04-04 2009-04-03 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
MX2010010904A MX2010010904A (en) 2008-04-04 2009-04-03 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof.
US12/870,774 US8399430B2 (en) 2008-04-04 2010-08-27 Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US12/870,763 US7855187B1 (en) 2008-04-04 2010-08-27 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods of making and using thereof
US13/069,860 US8343942B2 (en) 2008-04-04 2011-03-23 Methods for treating interstitial cystitis
US13/304,292 US8329673B2 (en) 2008-04-04 2011-11-23 Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US13/735,124 US8951990B2 (en) 2008-04-04 2013-01-07 Use of alkylated semi-synthetic glycosaminoglycosan ethers for the treatment of dental disorders
US14/613,523 US9549945B2 (en) 2008-04-04 2015-02-04 Use of alkylated semi-synthetic glycosaminoglycosan ethers for the treatment of inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4231008P 2008-04-04 2008-04-04
US61/042,310 2008-04-04

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/870,774 Continuation-In-Part US8399430B2 (en) 2008-04-04 2010-08-27 Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof
US12/870,763 Continuation-In-Part US7855187B1 (en) 2008-04-04 2010-08-27 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods of making and using thereof
US13/304,292 Continuation-In-Part US8329673B2 (en) 2008-04-04 2011-11-23 Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof

Publications (2)

Publication Number Publication Date
WO2009124266A2 WO2009124266A2 (en) 2009-10-08
WO2009124266A3 true WO2009124266A3 (en) 2009-12-17

Family

ID=41055226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039498 WO2009124266A2 (en) 2008-04-04 2009-04-03 Alkylated sem-synthetic glycosaminoglycosan ethers, and methods for making and using thereof

Country Status (10)

Country Link
US (5) US8399430B2 (en)
EP (1) EP2281008B1 (en)
JP (1) JP5758797B2 (en)
KR (1) KR101594552B1 (en)
CN (1) CN102177180A (en)
AU (1) AU2009231634B2 (en)
BR (1) BRPI0909849A2 (en)
CA (1) CA2719666C (en)
MX (1) MX2010010904A (en)
WO (1) WO2009124266A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2280720T1 (en) 2008-03-27 2019-06-28 Purdue Research Foundation Collagen-binding synthetic peptidoglycans, preparation, and methods of use
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
MX2010010904A (en) * 2008-04-04 2010-11-04 Univ Utah Res Found Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof.
US20130035307A1 (en) * 2010-01-26 2013-02-07 University Of Utah Research Foundation Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
JP2013521300A (en) * 2010-03-03 2013-06-10 ネオキュティス エスアー Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
WO2012129461A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
KR20140042795A (en) * 2011-03-23 2014-04-07 유니버시티 오브 유타 리서치 파운데이션 Methods for treating or preventing urological inflammation
ES2708076T3 (en) 2011-05-24 2019-04-08 Symic Ip Llc Synthetic peptidoglycans that bind to hyaluronic acid, preparation and methods of use
JP5873319B2 (en) * 2011-12-16 2016-03-01 株式会社コーセー Maillard reaction inhibitor
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
JP6543467B2 (en) 2011-12-19 2019-07-10 ディラホア アクチエボラゲット Non-anticoagulant glycosaminoglycans containing disaccharide repeating units and their medical use
LT2846809T (en) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
EP2849773A1 (en) * 2012-05-14 2015-03-25 University of Southern California Methods for limiting development of a skin wound
US9717752B2 (en) 2012-05-15 2017-08-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Uses of antagonists of hyaluronan signaling
JP6359554B2 (en) * 2012-12-12 2018-07-18 ソルベイ スペシャルティ ポリマーズ イタリー エス．ピー．エー． Fluorinated chitosan derivatives
JP6603650B2 (en) 2013-03-15 2019-11-06 パーデュー・リサーチ・ファウンデーション Extracellular matrix-bound synthetic peptidoglycan
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
US9492474B2 (en) 2013-07-10 2016-11-15 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
EP3060243A4 (en) * 2013-10-22 2017-03-29 Cantex Pharmaceuticals, Inc. Methods of treating and preventing radiation damage
AU2014352672B2 (en) * 2013-11-25 2018-11-29 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US9637712B2 (en) 2014-01-10 2017-05-02 Lost Spirits Distillery, Llc Method for rapid maturation of distilled spirits using light and heat processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
US9637713B2 (en) 2014-01-10 2017-05-02 Lost Spirits Distillery, Llc Method for rapid maturation of distilled spirits using light and heat processes
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
CN108135926A (en) 2015-09-24 2018-06-08 基质生物研究所 High resiliency hyaluronic acid compositions and its application method
ITUB20155623A1 (en) * 2015-11-16 2017-05-16 Fidia Farm Spa Improved process for the production of high purity sulphated HA
US11337994B2 (en) 2016-09-15 2022-05-24 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
US10849914B2 (en) 2017-06-12 2020-12-01 University Of Utah Research Foundation Methods for producing chemoembolic agents for the delivery of anti-cancer agents
KR20200026263A (en) 2017-07-07 2020-03-10 시믹 아이피, 엘엘씨 Synthetic bioconjugates
WO2019079535A1 (en) * 2017-10-18 2019-04-25 Glycomira Therapeutics, Inc. Methods and compositions for treating chronic rhinosinusitis
CN108586574B (en) * 2018-04-26 2019-11-12 国家海洋局第三海洋研究所 Aminoglucose glycopeptide compound and the preparation method and application thereof
CN111228653A (en) * 2018-11-13 2020-06-05 格莱科米拉治疗公司 Method for enhancing cancer treatment with ionizing radiation
WO2020159690A1 (en) 2019-01-30 2020-08-06 Bausch & Lomb Incorporated Crosslinked polymeric network and use thereof
WO2022157314A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid for use on the skin
WO2022157307A1 (en) * 2021-01-22 2022-07-28 Dsm Ip Assets B.V. Hyaluronic acid as antimicrobial agent for use on the skin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199687A1 (en) * 2002-04-11 2003-10-23 Manssur Yalpani Biocompatible materials and probes
FR2864090A1 (en) * 2003-12-19 2005-06-24 Aventis Pharma Sa New carboxy-reduced and selectively O-sulfated hyaluronic acid derivatives, useful for treating e.g. articular degeneration or disorders of bone metabolism, are inhibitors of matrix metalloproteases
WO2007006403A2 (en) * 2005-07-07 2007-01-18 Fidia Advanced Biopolymers S.R.L. Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599172A (en) 1948-11-29 1952-06-03 Searle & Co Sulfuric acid esters of hyaluronic acid and processes for the production thereof
US4240163A (en) * 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
FR2584728B1 (en) 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
SE453394B (en) 1986-07-07 1988-02-01 Pharmacia Ab PROCEDURE FOR PREPARING SULPHATATED POLYSACcharides BY USING A REDUCING AGENT FOR THE SULPHATING REACTION
EP0285357A3 (en) 1987-03-31 1989-10-25 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Control of retroviruses
DK505588D0 (en) 1988-02-26 1988-09-09 Jesper Hamburger MEDIUM AND USE OF SAME
IT1217458B (en) 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S SULFOAMINO DERIVATIVES OF CONDROITIN SULPHATES, DERMATAN SULPHATE AND HYALURONIC ACID AND THEIR PHARMACOLOGICAL PROPERTIES
JP2769584B2 (en) * 1990-06-04 1998-06-25 参天製薬株式会社 Antiallergic agent for topical administration
IT1247175B (en) 1991-04-19 1994-12-12 Fidia Spa PROCEDURE FOR PURIFICATION OF HYALURONIC ACID AND FRACTION OF PURE HYALURONIC ACID FOR OPHTHALMIC USE.
EP0601055B1 (en) 1991-08-16 2000-06-07 GALIN, Miles A. Medicament coated refractive anterior chamber ocular implant
ITPD940054A1 (en) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl SULPHATED POLYSACCHARIDES
WO1996024362A1 (en) 1995-02-07 1996-08-15 Shiseido Company, Ltd. Antiinflammatory agents
GB2317182B (en) 1996-09-11 2000-11-01 Johnson & Johnson Medical Sulfated polysaccharides and uses thereof in medical treatment
JPH10195107A (en) 1997-01-10 1998-07-28 Shiseido Co Ltd Sulfated oligohyaluronic acid
ES2189166T3 (en) 1997-04-04 2003-07-01 Fidia Advanced Biopolymers Srl N-SULFATED HIALURONIC ACID COMPOUNDS, ITS DERIVATIVES AND PROCESS FOR PREPARATION.
US5981509A (en) 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
IT1293484B1 (en) 1997-06-11 1999-03-01 Fidia Advanced Biopolymers Srl BIOLOGICAL MATERIAL INCLUDING AN EFFICIENT CELL CULTURE AND A BIOCOMPATIBLE AND BIODEGRADABLE THREE-DIMENSIONAL MATRIX
IT1294797B1 (en) 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS WITH PHYSICAL AND BUFFERING HEMOSTATIC ACTIVITIES
ITPD980037A1 (en) 1998-02-25 1999-08-25 Fidia Advanced Biopolymers Srl SULFATED HYALURONIC ACID AND ITS DERIVATIVES COVALENTLY LINKED TO SYNTHETIC POLYMERS FOR THE PREPARATION OF BIOMATERIALS AND FOR COATING
DE19813234A1 (en) 1998-03-26 1999-09-30 Knoell Hans Forschung Ev Production of sulfated hyaluronic acid with high degree of sulfation useful as anticoagulant, antiinflammatory agent, hydrogel component, etc.
JPH11279042A (en) 1998-03-30 1999-10-12 Shiseido Co Ltd Skin preparation for external use
US6984667B2 (en) 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
ITPD980149A1 (en) 1998-06-17 1999-12-17 Fidia Advanced Biopolymers Srl THREE-DIMENSIONAL PROSTHESES INCLUDING HYALURONIC ACID DERIVATIVES TO REPAIR OR REBUILD DAMAGED TISSUES AND PROCESS FOR THE
DE69918523T2 (en) 1998-07-31 2005-07-28 Seikagaku Corp. NEW GLYCOSAMINOGLYCAN AND THIS MEDICAMENT CONTAINING
IT1303735B1 (en) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S CROSS-LINKED HYALURONIC ACIDS AND THEIR MEDICAL USES.
IT1306644B1 (en) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl THREE-DIMENSIONAL STRUCTURES INCLUDING HYALURONIC ACID DERIVATIVES OBTAINABLE THROUGH SUPERCRITICAL ANTI-SOLVENT TECHNIQUE.
US6288043B1 (en) 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
JP2001097997A (en) 1999-10-01 2001-04-10 Shiseido Co Ltd Carrier for affinity absorption from sulfated hyaluronic acid, and its use
JP4139029B2 (en) * 1999-12-10 2008-08-27 大阪瓦斯株式会社 Power supply
JP2001163789A (en) 1999-12-13 2001-06-19 Maruho Co Ltd Medicine composition for matrix metalloprotease inhibitor
JP4782966B2 (en) 2000-01-10 2011-09-28 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド Use of lipid conjugates in the treatment of disease
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
IT1317359B1 (en) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl PERCARBOXYLATE POLYSACCHARIDES, SUCH AS HYALURONIC ACID, PROCESS FOR THEIR PREPARATION AND USE IN THE PHARMACEUTICAL FIELD AND
DE10053053A1 (en) 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmaceutical formulations for the inhibition of inflammatory arthritis
ITPD20020064A1 (en) 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl FOREIGN DERIVATIVES OF HYALURONIC ACID FOR THE PREPARATION OF HYDROGELD FOR USE IN THE BIOMEDICAL, SANITARY AND SURGICAL FIELD AND AS A SYSTEM
US7090829B2 (en) 2002-04-11 2006-08-15 Carbomer, Inc. Imaging probes
IL165910A0 (en) 2002-07-03 2006-01-15 Pericor Science Inc Compositions of hyaluronic acid and methods of use
JP2004262777A (en) * 2003-02-27 2004-09-24 Shiseido Co Ltd Acetylated hyaluronic acid-containing ocular medicinal preparation
DE10352137A1 (en) 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Use of sulfated hyaluronic acid
ZA200604869B (en) 2003-12-04 2007-11-28 Univ Utah Res Found Modified macromolecules and methods of making and using thereof
US20050203056A1 (en) 2003-12-19 2005-09-15 Aventis Pharma S.A. Carboxyl-reduced derivatives of hyaluronic acid, preparation thereof, use thereof as a medicinal product and the pharmaceutical compositions containing them
ITPD20040245A1 (en) 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl BIOMATERIALS MADE UP OF HYALURONIC ACID, SULFATE AND GELL, USABLE IN THE PREVENTION OF SPINAL ADHESIONS
DE102005004643B4 (en) 2005-01-28 2010-04-08 Innovent E.V. Technologieentwicklung Antiviral combinations and their use
JP2006206849A (en) 2005-01-31 2006-08-10 Seikagaku Kogyo Co Ltd Method for producing alkyl esterified glycosaminoglycan
WO2006105313A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions of and methods of using oversulfated glycosaminoglycans
WO2006108022A1 (en) 2005-04-04 2006-10-12 Neoparin, Inc. Process for the induction of intramolecular migration of sulfates, phosphates, and other oxyanions
US7993678B2 (en) 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
ES2616295T3 (en) 2005-10-12 2017-06-12 Seikagaku Corporation Agent to apply to mucosa and procedure for its production
US8039447B2 (en) 2005-11-22 2011-10-18 Centre National De La Recherche Scientifique (C.N.R.S.) Derivatives of hyaluronic acid, their preparation process and their uses
US20070166266A1 (en) 2006-01-19 2007-07-19 Solazyme, Inc. Methods and compositions for improving the health and appearance of skin
JP5399716B2 (en) 2006-03-02 2014-01-29 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ Aryl / alkyl vinyl sulfone hyaluronic acid derivatives
ITPD20060219A1 (en) 2006-05-31 2007-12-01 Fidia Farmaceutici PHARMACEUTICAL COMPOSITIONS CONTAINING HYALURONIC ACID SULFATED IN THE TREATMENT OF OSTEOARTHROSIS
CN101511876A (en) 2006-07-11 2009-08-19 犹他大学研究基金会 Macromolecules modified with electrophilic groups and methods of making and using thereof
EP2070518A2 (en) 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
TW200838552A (en) 2007-01-25 2008-10-01 Novozymes Biopolymer As Methyl esters of hyaluronic acid
JP5088864B2 (en) 2007-03-16 2012-12-05 オリンパス株式会社 Biological tissue filling material and manufacturing method thereof
EP2025687A1 (en) 2007-07-23 2009-02-18 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
US20100249064A1 (en) * 2007-09-07 2010-09-30 University Of Chicago Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan
EP2057983A1 (en) 2007-11-07 2009-05-13 Bruschettini S.r.l. Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations
WO2009111159A2 (en) 2008-03-03 2009-09-11 New York University Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same
MX2010010904A (en) 2008-04-04 2010-11-04 Univ Utah Res Found Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof.
US8343942B2 (en) 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
WO2010087207A1 (en) 2009-02-02 2010-08-05 大塚化学株式会社 Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
IT1393945B1 (en) 2009-04-21 2012-05-17 Fidia Farmaceutici COMPOSITIONS INCLUDING HYALURONIC ACID, HYALURONIC ACID, SULFATE, CALCIUM AND VITAMIN D3 IN THE TREATMENT OF OSTEOARTICULAR AND MUSCULOSCHELETAL DISEASES
IT1397247B1 (en) 2009-05-14 2013-01-04 Fidia Farmaceutici NEW REGULATORY AGENTS OF CYTOKINIC ACTIVITY
IT1397246B1 (en) 2009-05-14 2013-01-04 Fidia Farmaceutici NEW MEDICATIONS FOR TOPIC USE BASED HYALURONIC ACID SULFATED AS AN ACTIVATING OR INHABITING CITHOCINIC ACTIVITY
WO2012129461A1 (en) 2011-03-23 2012-09-27 University Of Utah Research Foundation Methods for treating or preventing urological inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199687A1 (en) * 2002-04-11 2003-10-23 Manssur Yalpani Biocompatible materials and probes
FR2864090A1 (en) * 2003-12-19 2005-06-24 Aventis Pharma Sa New carboxy-reduced and selectively O-sulfated hyaluronic acid derivatives, useful for treating e.g. articular degeneration or disorders of bone metabolism, are inhibitors of matrix metalloproteases
WO2007006403A2 (en) * 2005-07-07 2007-01-18 Fidia Advanced Biopolymers S.R.L. Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABATANGELO G ET AL: "Biocompatibility and enzymatic degradation studies on sulphated hyaluronic acid derivatives", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 18, no. 21, 1 January 1997 (1997-01-01), pages 1411 - 1415, XP004092620, ISSN: 0142-9612 *
BENESOVÁ K ET AL: "Stability evaluation of n-alkyl hyaluronic acid derivates by DSC and TG measurement", JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 83, no. 2, 1 February 2006 (2006-02-01), pages 341 - 348, XP019255848, ISSN: 1572-8943 *
R.W. JEANLOZ: "The methyl ester of methylated hyaluronic acid", J. BIOL. CHEM., vol. 197, 1952, pages 141 - 150, XP002550040 *

Also Published As

Publication number Publication date
CA2719666A1 (en) 2009-10-08
US8329673B2 (en) 2012-12-11
AU2009231634A1 (en) 2009-10-08
US20150209385A1 (en) 2015-07-30
EP2281008B1 (en) 2017-01-04
US20130190234A1 (en) 2013-07-25
BRPI0909849A2 (en) 2015-10-06
US7855187B1 (en) 2010-12-21
MX2010010904A (en) 2010-11-04
CA2719666C (en) 2016-08-16
JP5758797B2 (en) 2015-08-05
US8951990B2 (en) 2015-02-10
CN102177180A (en) 2011-09-07
WO2009124266A2 (en) 2009-10-08
US8399430B2 (en) 2013-03-19
AU2009231634A2 (en) 2012-04-12
US9549945B2 (en) 2017-01-24
EP2281008A2 (en) 2011-02-09
KR101594552B1 (en) 2016-02-17
US20110082104A1 (en) 2011-04-07
US20100317616A1 (en) 2010-12-16
JP2011516672A (en) 2011-05-26
US20120058161A1 (en) 2012-03-08
AU2009231634B2 (en) 2014-05-15
KR20110004422A (en) 2011-01-13

Similar Documents

Publication Publication Date Title
WO2009124266A3 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
CY1112320T1 (en) TAPENDADOL TITLE
TW200833330A (en) Substituted dihydropyrazolones and their use
EP2358378A4 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
WO2007144327A3 (en) Phenyl-pyrazole derivatives as non-steroidal glucocoricoid receptor ligands
WO2006099169A3 (en) Novel liposome compositions
WO2007030666A3 (en) Medicated skin care preparation for promoting wound healing
TW200635924A (en) Chemical compounds
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
GB0620385D0 (en) Novel compounds
TW200719882A (en) Treatment of connective tissue diseases of the skin
WO2011127302A3 (en) Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
IL206443A0 (en) Polysaccharide derivatives of lipoic acid, their preparation, use as skin cosmetics and medical devices
IL206815A (en) Cyclic triazo and diazo channel blockers, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for the treatment of diseases
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
IN2012DN03182A (en)
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
WO2009109654A3 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40
WO2008119097A8 (en) Pharmaceutical substance for itching and pain
GT201300125A (en) 1H-PIRAZOL-5-SUBSTITUTED SODIUM OLATO
WO2010121675A3 (en) Thiazolyl-benzimidazoles
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
CL2007002652A1 (en) COMPOUNDS DERIVED FROM ISOSERINE, INHIBITORS OF THE BLOOD COAGULATION FACTOR IXA; PREPARATION PROCEDURE; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ACCOMPANIED DISEASES OF THROMBOSIS, EMBOLIES, HYPERCOAGULABILITY OR CHANGES

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980120897.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09727633

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2719666

Country of ref document: CA

Ref document number: 2026/MUMNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011503216

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/010904

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009231634

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20107024824

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009727633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009727633

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009231634

Country of ref document: AU

Date of ref document: 20090403

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0909849

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100930